Loading
LaunXP Biomedical develops new cancer drugs and new uses or forms of existing ones. Its first new compound to reach people is in an early trial in advanced solid tumours in Taiwan.
LaunXP Biomedical Co., Ltd., at No. 402 Shizheng Road, Xitun District, Taichung, Taiwan, has worked in oncology and metabolic disease since its inception in 2015, according to the company, on two tracks: new chemical entities (505(b)(1)) and repositioned or reformulated existing drugs (505(b)(2)). Its pipeline lists LXP108, a multi-target agent for solid tumours including renal, liver and pancreatic cancer, in phase 1; LXP109 for non-small cell lung cancer with phase 2/3 in planning; LXP107 for acute myeloid leukaemia and LXP103 for metabolic disorders in preclinical work; and LXP105, a 505(b)(2) programme for triple-negative breast cancer with phase 2 in planning. Its registered trial tests LXP1788 injection, given intravenously through an implanted port, in advanced solid tumours. Its first registered cancer trial, NCT06883539, was posted on ClinicalTrials.gov in March 2025. The company publishes investor, governance and shareholder information on its website.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/